Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label study to assess the pharmacokinetics, safety and tolerability of siponimod in healthy subjects with CYP2C9 extensive (EM) and poor metabolizer (PM) phenotype

Trial Profile

Open-label study to assess the pharmacokinetics, safety and tolerability of siponimod in healthy subjects with CYP2C9 extensive (EM) and poor metabolizer (PM) phenotype

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Aug 2018 Results (n=24) published in the Clinical Pharmacokinetics.
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Status changed from not yet recruiting to completed, as per results presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top